A phase II trial of oral panobinostat (LBH589), a no deacetylase inhibitor (DACi) in patients with primary myelofibrosis (PMF), post-essential thrombocythemia (ET) myelofibrosis, and post-polycythemia vera (PV) myelofibrosis

被引：1
|
作者：
DeAngelo, D. J.
Tefferi, A.
Mesa, R. A.
Paley, C. S.
Wadleigh, M.
Snyder, D.
Ondovik, M. S.
Rine, J.
Bhalla, K. N.
机构：
[1] Harvard Univ, Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Mayo Clin Rochester, Rochester, MN USA
[3] Mayo Clin Arizona, Scottsdale, AZ USA
[4] Novartis Pharmaceut, E Hanover, NJ USA
[5] City Hope Natl Med Ctr, Duarte, CA USA
[6] Med Coll Georgia, Ctr Canc, Augusta, GA 30912 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.tps283
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS283
引用
收藏
页数：1
相关论文
共 50 条
  • [41] A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis
    A Quintás-Cardama
    W Tong
    H Kantarjian
    D Thomas
    F Ravandi
    S Kornblau
    T Manshouri
    J E Cortes
    G Garcia-Manero
    S Verstovsek
    Leukemia, 2008, 22 : 965 - 970
  • [42] Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project
    Mora, Barbara
    Giorgino, Toni
    Guglielmelli, Paola
    Rumi, Elisa
    Maffioli, Margherita
    Rambaldi, Alessandro
    Caramella, Marianna
    Komrokji, Rami
    Gotlib, Jason
    Kiladjian, Jean Jacques
    Cervantes, Francisco
    Devos, Timothy
    Palandri, Francesca
    De Stefano, Valerio
    Ruggeri, Marco
    Silver, Richard T.
    Benevolo, Giulia
    Albano, Francesco
    Cavalloni, Chiara
    Barraco, Daniela
    Merli, Michele
    Pietra, Daniela
    Casalone, Rosario
    Barbui, Tiziano
    Rotunno, Giada
    Cazzola, Mario
    Vannucchi, Alessandro Maria
    Passamonti, Francesco
    HAEMATOLOGICA, 2018, 103 (09) : E392 - E394
  • [43] The JAK Inhibitor, INCB018424, Demonstrates Durable and Marked Clinical Responses in Primary Myelofibrosis (PMF) and Post-Polycythemia/Essential Thrombocythemia Myelofibrosis (Post PV/ET-MF)
    Verstovsek, Srdan
    Kantarjian, Hagop M.
    Pardanani, Animesh D.
    Thomas, Deborah
    Cortes, Jorge
    Mesa, Ruben A.
    Hogan, William J.
    Redman, John R.
    Erickson-Viitanen, Sue
    Levy, Richard
    Vaddi, Kris
    Bradley, Edward
    Fridman, Jordan
    Tefferi, Ayalew
    BLOOD, 2008, 112 (11) : 622 - 622
  • [44] THE SELECTIVE JANUS KINASE (JAK) INHIBITOR, INCB018424, SHOWS EFFICACY IN A PHASE I/II TRIAL IN PATIENTS WITH PRIMARY MYELOFIBROSIS (PMF) AND POST POLYCYTHEMIA VERA/ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS (POST-PV/ET MF)
    Verstovsek, S.
    Kantarjian, H.
    Pardanani, A.
    Thomas, D.
    Cortes, J.
    Mesa, R.
    Hogan, W.
    Redman, J.
    Levy, R.
    Vaddi, K.
    Fridman, J.
    Tefferi, A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 179 - 179
  • [45] Efficacy and safety of JAK inhibitor INC424 in patients with primary and post-polycythemia vera or post-essential thrombocythemia myelofibrosis in the Chinese population
    Xin Du
    Daobin Zhou
    Frontiers of Medicine, 2016, 10 : 437 - 443
  • [46] Efficacy and safety of JAK inhibitor INC424 in patients with primary and post-polycythemia vera or post-essential thrombocythemia myelofibrosis in the Chinese population
    Xin Du
    Daobin Zhou
    Frontiers of Medicine, 2016, 10 (04) : 437 - 443
  • [47] Efficacy and safety of JAK inhibitor INC424 in patients with primary and post-polycythemia vera or post-essential thrombocythemia myelofibrosis in the Chinese population
    Du, Xin
    Zhou, Daobin
    FRONTIERS OF MEDICINE, 2016, 10 (04) : 437 - 443
  • [48] Population Pharmacokinetic Analysis of Orally-Administered Ruxolitinib (INCB018424 Phosphate) in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia Myelofibrosis (PET MF)
    Chen, Xuejun
    Williams, William V.
    Sandor, Victor
    Yeleswaram, Swamy
    JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 53 (07): : 721 - 730
  • [49] Interim Analysis of a Phase II Pilot Trial of Ruxolitinib Combined with Danazol for Patients with Primary Myelofibrosis (MF), Post Essential Thrombocythemia-Myelofibrosis (Post ET), and Post Polycythemia Vera Myelofibrosis (PV MF) Suffering from Anemia
    Gowin, Krisstina L.
    Dueck, Amylou C.
    Mascarenhas, John O.
    Hoffman, Ronald
    Reeder, Craig B.
    Camoriano, John
    Gano, Katherine
    Ghurye, Vineta
    Reddy, Sravan Nagi
    Koenig, Patricia
    Fauble, Veena
    Tibes, Raoul
    Mesa, Ruben
    BLOOD, 2014, 124 (21)
  • [50] A phase II study of vorinostat (MK-0683) in patients with primary myelofibrosis and post-polycythemia vera myelofibrosis
    Andersen, Christen L.
    Mortensen, Nana B.
    Klausen, Tobias W.
    Vestergaard, Hanne
    Bjerrum, Ole W.
    Hasselbalch, Hans C.
    HAEMATOLOGICA, 2014, 99 (01)
12345